Synonym
Renin inhibitory peptide, statine; Iva-his-pro-phe-his-sta-leu-phe-NH2; SCRIP;
IUPAC/Chemical Name
(S)-N-((S)-1-(((S)-1-(((3S,4S)-1-(((2S,3S)-1-(((S)-1-amino-1-oxo-3-phenylpropan-2-yl)amino)-3-methyl-1-oxopentan-2-yl)amino)-3-hydroxy-6-methyl-1-oxoheptan-4-yl)amino)-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-1-(((R)-2-amino-2-methylbutanoyl)-L-histidyl)pyrrolidine-2-carboxamide
InChi Key
SZMATORSVSGBIL-IDSKXIRVSA-N
InChi Code
InChI=1S/C54H77N13O9/c1-7-33(5)46(51(74)62-39(47(55)70)23-34-16-11-9-12-17-34)66-45(69)27-44(68)38(22-32(3)4)61-49(72)41(25-36-28-57-30-59-36)63-48(71)40(24-35-18-13-10-14-19-35)64-50(73)43-20-15-21-67(43)52(75)42(26-37-29-58-31-60-37)65-53(76)54(6,56)8-2/h9-14,16-19,28-33,38-44,46,68H,7-8,15,20-27,56H2,1-6H3,(H2,55,70)(H,57,59)(H,58,60)(H,61,72)(H,62,74)(H,63,71)(H,64,73)(H,65,76)(H,66,69)/t33-,38-,39-,40-,41-,42-,43-,44-,46-,54+/m0/s1
SMILES Code
O=C(N)[C@H](CC1=CC=CC=C1)NC([C@H]([C@@H](C)CC)NC(C[C@H](O)[C@@H](NC([C@H](CC2=CNC=N2)NC([C@H](CC3=CC=CC=C3)NC([C@H]4N(C([C@H](CC5=CNC=N5)NC([C@@](C)(CC)N)=O)=O)CCC4)=O)=O)=O)CC(C)C)=O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
1,052.29
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Blaine EH, Schorn TW, Boger J. Statine-containing renin inhibitor. Dissociation of blood pressure lowering and renin inhibition in sodium-deficient dogs. Hypertension. 1984 Mar-Apr;6(2 Pt 2):I111-8. PubMed PMID: 6373590.
2: Hui KY, Carlson WD, Bernatowicz MS, Haber E. Analysis of structure-activity relationships in renin substrate analogue inhibitory peptides. J Med Chem. 1987 Aug;30(8):1287-95. PubMed PMID: 3302256.
3: Leckie BJ, Grant J, Hallett A, Hughes M, Jones DM, Szelke M, Tree M. Peptide inhibitors of renin. Scott Med J. 1984 Apr;29(2):125-6. PubMed PMID: 6397858.
4: Veber DF, Bock MG, Brady SF, Ulm EH, Cochran DW, Smith GM, LaMont BI, Dipardo RM, Poe M, Freidinger RM, et al. Renin inhibitors containing 2-substituted statine. Biochem Soc Trans. 1984 Dec;12(6):956-9. PubMed PMID: 6442237.
5: Blaine EH. Characteristics of the blood pressure lowering action of renin inhibition and comparison with angiotensin converting enzyme inhibition. J Hypertens Suppl. 1989 Apr;7(2):S47-9. PubMed PMID: 2666614.
6: Veber DF, Payne LS, Williams PD, Perlow DS, Lundell GF, Gould NP, Siegl PK, Sweet CS, Freidinger RM. Design and discovery in the development of long-acting renin inhibitors. Biochem Soc Trans. 1990 Dec;18(6):1291-4. PubMed PMID: 2088926.
7: Sweet CS, Ludden CT, Frederick CM, Ribeiro LG. Hemodynamic effects of angiotensin and renin inhibition in dogs with acute left ventricular failure. Am J Med. 1984 Aug 20;77(2A):7-12. PubMed PMID: 6089558.
8: Sweet CS, Ludden CT, Frederick CM, Bush LR, Ribeiro LG. Comparative hemodynamic effects of MK-422, a converting enzyme inhibitor, and a renin inhibitor in dogs with acute left ventricular failure. J Cardiovasc Pharmacol. 1984 Nov-Dec;6(6):1067-75. PubMed PMID: 6084762.
